目的 建立基于决策树解读万古霉素血药浓度的模式，并将其应用于临床实践。方法 临床药师依据万古霉素血药浓度监测结果和患者病程，应用决策树对血药浓度作解读。当需要调整剂量时，应用群体药动学模型的贝叶斯反馈程序估算患者个体化给药剂量，辅助临床个体化用药。结果 决策树应用于临床万古霉素血药浓度的解读，能为临床制定万古霉素给药方案提供依据。结论 基于决策树的万古霉素个体化血药浓度解读模式可协助医师个体化用药，提高万古霉素的临床疗效以及减少相关不良反应。
Abstract
OBJECTIVE Decision tree is established for the interpretation of vancomycin(VCM) serum concentration, and is applied in clinical practice. METHODS Decision tree is applied for VCM interpretation based on the serum concentration and the course of disease. The Bayesian feedback procedure of population pharmacokinetics model is utilized for adjustment of VCM dosage, which is helpful for VCM individualization. RESULTS Decision tree is applied for the interpretation of VCM serum concentration, which could provide basis for the establishment of VCM dosage regimen. CONCLUSION The pattern of applying decision tree to interpretate VCM serum concentration is helpful for individualized dosing, which would improve the effect and reduce the relative side effect of VCM.
关键词
决策树 /
万古霉素 /
治疗药物监测 /
临床药师
{{custom_keyword}} /
Key words
decision tree /
vancomycin /
therapeutics drug monitoring /
clinical pharmacist
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HE X R, LIU Z H, JI S M. Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people . Acta Pharm Sin(药学学报), 2014, 49(11):1528-1535.
[2] RYBAK M J. The pharmacokinetic and pharmacodynamic properties of vancomycin . Clin Infect Dis, 2006, 42 (suppl 1):35-39.
[3] CHARLES P G, WARD P B, JOHNSON P D, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis, 2004, 38(3):448-451.
[4] WONG-BERINGER A, JOO J, TSE E, et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy . Int J Antimicrob Agents, 2011, 37(2): 95-101.
[5] GOULD F K, 0-BRINDLE R, CHADWICK P R, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom . J Antimicrob Chemother, 2009, 63(5):849-861.
[6] LAI D F, CHEN X D. Early diagnosis and prediction of portal hypertension complicated with portal vein thrombosis spleen resection based on the decision tree. J Huzhou Teach Coll(湖州师范学院学报), 2013, 35(6):69-73.
[7] SUN X L, CHE L J, YU J. Based on ID3 algorithm of decision tree for the forecast of hospitalization days. J Mathematical Med(数理医药学会杂志), 2011, 24(4):382-384.
[8] LIN W W, WU W, ZHENG J, et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol, 2016, 72(1):29-37.
[9] HE X R, LU W, ZOU D, et al. Advance on population pharmacokinetic models of vancomycin. Chin Pharm J(中国药学杂志), 2013, 48(2):2075-2080.
KAZUAKI M, YOSHIO T, NORIO O, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother, 2013, 19(3):365-380.
RYBAK M, LOMAESTRO B, ROTSCHAFER J C, et al. Therapeutic monitoring of vancomycin in adultpatients: a consensus review of the American society of health-system pharmacists, the infectiousdiseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm, 2009, 66(1):82-98.
HU J L, ZHANG J. Research up dates of vancomycin nephrotoxicity. Chin J Infect Chemother(中国感染与化疗杂志), 2013, 13(5) :394-399.
LODISE T P, PATEL N, LOMAESTRO B M, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis, 2009, 49(4):507-514.
SAKOULAS G, GOLD H S, COHEN R A, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus(MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother, 2006, 57(4):699-704.
CHEN B, YANG W H. Application of population pharmacokinetics in the therapeutic drug monitoring of vancomycin. Chin J Clin Pharmacol(中国临床药理学杂志), 2011, 27(9):713-717.
YE Z K,LI X G,ZHAI S D.Therapeutic drug monitoring of vancomycinin chian: current status andevaluation. Chin J Clin Pharmacol(中国临床药理学杂志), 2013, 29(7):545-548.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(729 KB)
